GlassScriptPhysician profile
Ginger D Mullins
NPI 1659469690
$9,021.59
in general payments reported to CMS, 2019-2025
49 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,878 · 2022: $865 · 2023: $1,988 · 2024: $2,181 · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,278.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,892.95 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,236.29 | 2021-2025 | |
| Lilly USA, LLC | $1,025.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $712.37 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $432.95 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.50 | 2021-2025 | Jardiance |
| Abbott Laboratories | $359.51 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $290.81 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $245.31 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $232.57 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $190.53 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $187.06 | 2021-2025 | Gvoke Hypopen |
| Eisai INC. | $129.15 | 2021-2025 | |
| Astellas Pharma US INC | $117.54 | 2023-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $117.21 | 2021 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $102.97 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $100.80 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.12 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $76.14 | 2021-2025 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $75.00 | 2022 | |
| Lundbeck LLC | $73.90 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $71.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $69.01 | 2025 | Auvelity |
| Amarin Pharma, INC. | $62.92 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $57.86 | 2024-2025 | Voquezna |
| Jazz Pharmaceuticals INC. | $55.88 | 2021 | |
| Medtronic, INC. | $53.01 | 2024-2025 | Kyphon Express II Kyphopak Tray, Inceptiv, Venaseal |
| Scilex Pharmaceuticals INC. | $51.43 | 2024 | |
| Sumitomo Pharma America, INC. | $44.21 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $43.59 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $41.66 | 2021-2023 | Steglatro, Belsomra |
| Mannkind Corporation | $38.58 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.27 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $35.73 | 2022 | |
| Almatica Pharma LLC | $31.08 | 2021 | |
| Supernus Pharmaceuticals, INC. | $27.98 | 2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $26.51 | 2022 | |
| Currax Pharmaceuticals LLC | $25.69 | 2021-2022 | |
| Nevro Corp. | $19.89 | 2023 | Senza |
| Dynavax Technologies Corporation | $19.67 | 2024 | Heplisav-B |
| Avion Pharmaceuticals | $18.01 | 2023 | Methylphenidate Hydrochloride |
| Hikma Pharmaceuticals USA | $16.50 | 2024 | Ryaltris |
| Horizon Therapeutics Plc | $16.33 | 2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $15.91 | 2024 | Livalo |
| Antares Pharma, INC. | $14.64 | 2023 | Tlando, Xyosted, Nocdurna |
| Alexion Pharmaceuticals, INC. | $14.08 | 2023 | Strensiq |
| Tolmar, INC. | $13.62 | 2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $13.60 | 2023 | |
| Arbor Pharmaceuticals, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.